FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912109348> ?p ?o ?g. }

• W2912109348 endingPage "4099" @default.
• W2912109348 startingPage "4099" @default.
• W2912109348 abstract "Abstract Background Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14) balanced translocation, involving on chromosome 11 the gene encoding cyclin D1, CCND1. The enhancer of IGH, on chromosome 11, induces aberrant Cyclin D1 overexpression. A few reports have shown that the CCND1 oncogene locus is a recurrently amplified region in MCL. However, the prognostic value of this copy number abnormality (CNA) is not known. The incidence and clinical impact of CCND1 CNA were investigated on diagnostic samples from patients enrolled in the first-line randomized controlled trial LyMa (S. Le Gouill et al. NEJM 2017). Patients and methods A series of 100 lymph node biopsies performed at diagnosis for patients enrolled in the LyMa trial (n=299) was selected. After DNA extraction, CNAs were investigated in these samples using the innovative Oncoscan® SNP-array technique adapted to analyze highly degraded DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues. Ninety-four samples were informative for CNAs. CCND1 gains were controlled by fluorescence in situ hybridization on interphase nuclei, following standard procedures using LSI IGH/CCND1 XT Dual color, dual fusion translocation probes (Abbott Molecular, Des Plaines, IL). Progression-free and overall survivals were calculated from the date of inclusion until relapse/death or last news and death or last news respectively. Cumulative incidence of relapse (CIR) was estimated from the date of inclusion until the date of relapse or last news Results Amplifications of a large portion of 11q, beginning at the t(11;14) breakpoint, were observed with Oncoscan® in 7 patients. All these cases with a gain of 11q13-14 (CCND1) also had a gain of the 14q32 locus (IGH) suggesting amplification of the rearranged IGH-CCND1 region of t(11;14). This was confirmed by FISH analysis which disclosed three different configurations. The first was the classical CCND1-IGH rearrangement (CCND1 on normal chromosome 11, IGH on normal chromosome 14 and two fusion signals from the t(11;14)(CCND1-IGH)). The second configuration associated CCND1-IGH fusion signals and a gain of both CCND1 and IGH signals. The third configuration was a duplication of a CCND1-IGH fusion signals (3 signals). Both in SNP and in FISH, the amplification was always identified as sub-clonal, concerning only part of the cells. In some patients, different configurations coexisted. Compared to other patients of the series, those with amplification of IGH and CCND1 regions had a higher-risk bio-MIPI (11q13-14, p=0.015; 14q32, p=0.004). Patients with large gains at 11q13-14 (CCND1 N=7) had poorer median PFS (18 months vs not reached (NR); p=0.004), OS (35 months vs NR; p=0.01) and CIR (33 months vs not NR; p=0.004). The same was observed for patients with gains at 14q32 (IGH; N=8), with significantly different median PFS (23 months vs NR; p<0.001), OS (38 months vs NR; p=0.001) and CIR (28 months vs NR; p<0.001). Conclusion Gains of the IGH-CCND1 rearrangement or involved genes appear to be a potential new biomarker predictive of poor response to first line immunochemotherapy in young MCL patients. Disclosures Hermine: Novartis: Research Funding; Hybrigenics: Research Funding; AB Science: Consultancy, Equity Ownership, Honoraria, Research Funding; Erythec: Research Funding; Celgene Corporation: Research Funding." @default.
• W2912109348 created "2019-02-21" @default.
• W2912109348 creator A5008743540 @default.
• W2912109348 creator A5009487344 @default.
• W2912109348 creator A5010173185 @default.
• W2912109348 creator A5014459735 @default.
• W2912109348 creator A5016122215 @default.
• W2912109348 creator A5033073385 @default.
• W2912109348 creator A5040579517 @default.
• W2912109348 creator A5041002394 @default.
• W2912109348 creator A5044172266 @default.
• W2912109348 creator A5051471778 @default.
• W2912109348 creator A5063349306 @default.
• W2912109348 creator A5064856085 @default.
• W2912109348 creator A5068303471 @default.
• W2912109348 creator A5068452218 @default.
• W2912109348 creator A5073612758 @default.
• W2912109348 creator A5074588502 @default.
• W2912109348 creator A5078197703 @default.
• W2912109348 creator A5079523601 @default.
• W2912109348 creator A5079890028 @default.
• W2912109348 creator A5088148467 @default.
• W2912109348 date "2018-11-29" @default.
• W2912109348 modified "2023-10-17" @default.
• W2912109348 title "Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group" @default.
• W2912109348 doi "https://doi.org/10.1182/blood-2018-99-113303" @default.
• W2912109348 hasPublicationYear "2018" @default.
• W2912109348 type Work @default.
• W2912109348 sameAs 2912109348 @default.
• W2912109348 citedByCount "0" @default.
• W2912109348 crossrefType "journal-article" @default.
• W2912109348 hasAuthorship W2912109348A5008743540 @default.
• W2912109348 hasAuthorship W2912109348A5009487344 @default.
• W2912109348 hasAuthorship W2912109348A5010173185 @default.
• W2912109348 hasAuthorship W2912109348A5014459735 @default.
• W2912109348 hasAuthorship W2912109348A5016122215 @default.
• W2912109348 hasAuthorship W2912109348A5033073385 @default.
• W2912109348 hasAuthorship W2912109348A5040579517 @default.
• W2912109348 hasAuthorship W2912109348A5041002394 @default.
• W2912109348 hasAuthorship W2912109348A5044172266 @default.
• W2912109348 hasAuthorship W2912109348A5051471778 @default.
• W2912109348 hasAuthorship W2912109348A5063349306 @default.
• W2912109348 hasAuthorship W2912109348A5064856085 @default.
• W2912109348 hasAuthorship W2912109348A5068303471 @default.
• W2912109348 hasAuthorship W2912109348A5068452218 @default.
• W2912109348 hasAuthorship W2912109348A5073612758 @default.
• W2912109348 hasAuthorship W2912109348A5074588502 @default.
• W2912109348 hasAuthorship W2912109348A5078197703 @default.
• W2912109348 hasAuthorship W2912109348A5079523601 @default.
• W2912109348 hasAuthorship W2912109348A5079890028 @default.
• W2912109348 hasAuthorship W2912109348A5088148467 @default.
• W2912109348 hasConcept C104317684 @default.
• W2912109348 hasConcept C121608353 @default.
• W2912109348 hasConcept C126322002 @default.
• W2912109348 hasConcept C142724271 @default.
• W2912109348 hasConcept C143998085 @default.
• W2912109348 hasConcept C199835354 @default.
• W2912109348 hasConcept C2777525834 @default.
• W2912109348 hasConcept C2777542201 @default.
• W2912109348 hasConcept C2779338263 @default.
• W2912109348 hasConcept C2780189214 @default.
• W2912109348 hasConcept C29537977 @default.
• W2912109348 hasConcept C30481170 @default.
• W2912109348 hasConcept C502942594 @default.
• W2912109348 hasConcept C53226629 @default.
• W2912109348 hasConcept C54355233 @default.
• W2912109348 hasConcept C71924100 @default.
• W2912109348 hasConcept C86803240 @default.
• W2912109348 hasConceptScore W2912109348C104317684 @default.
• W2912109348 hasConceptScore W2912109348C121608353 @default.
• W2912109348 hasConceptScore W2912109348C126322002 @default.
• W2912109348 hasConceptScore W2912109348C142724271 @default.
• W2912109348 hasConceptScore W2912109348C143998085 @default.
• W2912109348 hasConceptScore W2912109348C199835354 @default.
• W2912109348 hasConceptScore W2912109348C2777525834 @default.
• W2912109348 hasConceptScore W2912109348C2777542201 @default.
• W2912109348 hasConceptScore W2912109348C2779338263 @default.
• W2912109348 hasConceptScore W2912109348C2780189214 @default.
• W2912109348 hasConceptScore W2912109348C29537977 @default.
• W2912109348 hasConceptScore W2912109348C30481170 @default.
• W2912109348 hasConceptScore W2912109348C502942594 @default.
• W2912109348 hasConceptScore W2912109348C53226629 @default.
• W2912109348 hasConceptScore W2912109348C54355233 @default.
• W2912109348 hasConceptScore W2912109348C71924100 @default.
• W2912109348 hasConceptScore W2912109348C86803240 @default.
• W2912109348 hasIssue "Supplement 1" @default.
• W2912109348 hasLocation W29121093481 @default.
• W2912109348 hasOpenAccess W2912109348 @default.
• W2912109348 hasPrimaryLocation W29121093481 @default.
• W2912109348 hasRelatedWork W2012013136 @default.
• W2912109348 hasRelatedWork W2140729622 @default.
• W2912109348 hasRelatedWork W2142099049 @default.
• W2912109348 hasRelatedWork W2394154073 @default.
• W2912109348 hasRelatedWork W2414324871 @default.
• W2912109348 hasRelatedWork W2415533234 @default.
• W2912109348 hasRelatedWork W2912109348 @default.
• W2912109348 hasRelatedWork W2979960296 @default.
• W2912109348 hasRelatedWork W3030318556 @default.

• next